Changes in comorbid conditions after prolonged exposure for PTSD: A literature review by Minnen, A. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/139787
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
DISASTER PSYCHIATRY: TRAUMA, PTSD, AND RELATED DISORDERS (E FOA ANDAASNAANI, SECTION EDITORS)
Changes in Comorbid Conditions After Prolonged
Exposure for PTSD: a Literature Review
Agnes van Minnen & Lori A. Zoellner &
Melanie S. Harned & Katherine Mills
Published online: 5 March 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Prolonged exposure (PE) is an effective psycholog-
ical treatment for patients who suffer from PTSD. The major-
ity of PTSD patients have comorbid psychiatric disorders, and
some clinicians are hesitant to use PE with comorbid patients
because they believe that comorbid conditions may worsen
during PE. In this article, we reviewed the evidence for this
question: what are the effects of PE on comorbid symp-
toms and associated symptomatic features? We reviewed
findings from 18 randomized controlled trials of PE that
assessed the most common comorbid conditions (major
depression, anxiety disorders, substance use disorders,
personality disorders, and psychotic disorders) and addi-
tional symptomatic features (suicidality, dissociation, neg-
ative cognitions, negative emotions, and general health
and work/social functioning). Although systematic re-
search is not available for all comorbid populations, the
existing research indicates that comorbid disorders and
additional symptomatic features either decline along with
the PTSD symptoms or do not change as a result of PE.
Therefore, among the populations that have been studied
to date, there is no empirical basis for excluding PTSD pa-
tients from PE due to fear of increases in comorbid conditions
or additional symptomatic features. Limitations of the existing
research and recommendations for future research are also
discussed.
Keywords PTSD . Trauma . Exposure therapy .
Comorbidity . Secondary outcomes .Worsening
Introduction
Comorbidity is high in PTSD patients, as 80–90 % of individ-
uals with PTSD have one or more comorbid conditions and
two thirds have two or more additional diagnoses [1]. The
most common comorbid diagnoses include major depression,
anxiety disorders, substance use disorders, borderline person-
ality disorder, and psychotic disorders. In addition, some pa-
tients show additional symptomatic features such as
suicidality, dissociation, distorted and negative trauma-
related cognitions (e.g., self-blame, perceptions of the world
as extremely dangerous), persistent negative trauma-related
emotions (e.g., anger, guilt, shame), physical health problems,
and limited work and social functioning. Given that comor-
bidity is the norm rather than the exception among PTSD
patients, an important question to answer is how to optimally
treat PTSD patients with these comorbidities and associated
features.
Prolonged exposure (PE) is recommended as a first-line
treatment approach for PTSD (e.g., International Society for
Traumatic Stress Studies [2]; National Institute for Health and
Clinical Excellence Guidelines on PTSD [3]; for a meta-
analysis of PE, see [4]). The primary components of PE in-
clude imaginal exposure to the trauma memory followed by
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processing of the trauma memory as well as in vivo exposure
to feared but safe situations. The theorized mechanisms un-
derlying PE are based on emotional processing theory and
broader extinction models of fear reduction. Specifically, dys-
functional meaning associations underlying the trauma-
related fear are altered or disconfirmed via information obtain-
ed during the exposure exercises [5].
PE is a trauma-focused approach, which means that the
focus is primarily on processing the memory of the trauma
and its effects on the patient’s life and, accordingly, to directly
target trauma-related symptoms such as PTSD. Given this
focus, comorbid disorders or problems are not (or minimally)
addressed before or during treatment. Despite its efficacy, PE
is underused by clinicians, especially in cases of comorbidity
[6, 7]. One of the reasons clinicians may be hesitant to use PE
is due to fear that comorbid conditions, when left untreated,
will interfere with trauma-focused treatment. Another reason
for not using trauma-focused treatment approaches such as PE
is that clinicians are afraid that the comorbid conditions will
worsen when the trauma is directly processed.
In a previous review [8••], we addressed the first concern of
clinicians, namely, whether comorbid conditions contraindi-
cate the use of PE. The conclusion was that, although more
controlled studies are necessary, it is possible to effectively
and safely treat PTSD patients with many comorbid condi-
tions (e.g., major depression, dissociation, substance abuse)
with PE and without directly treating the comorbidity itself.
For more severe comorbidities such as serious self-injurious
behavior, acute suicidality, and substance dependence, it was
concluded that integrated or concurrent treatments that include
PE in combination with treatments or strategies targeting the
comorbid problem might be optimal. However, this prior re-
view did not address the second concern raised by clinicians,
namely, does PE lead to worsening of comorbid disorders and
associated problems? In the present review, we will address
the question of how comorbid symptoms and commonly as-
sociated features change as a result of PE.
There are several models to explain the relationship be-
tween PTSD and high comorbidity rates. It should be noted
that comorbidity technically refers to two separate underlying
causal entities existing simultaneously but independently [9].
However, for the purposes of this paper, we use the term
comorbidity to imply a shared association between two con-
structs. Some causal models propose that PTSD mediates the
relationship between trauma exposure and other comorbid
problems. For example, PTSD has been hypothesized to me-
diate the effects between traumatization and the course and
severity of severe mental illness both directly (through specif-
ic PTSD symptoms) or indirectly (through correlates of PTSD
[10]). Similarly, PTSD symptoms of re-experiencing and
avoidance/numbing have been found to mediate the relation-
ship between childhood sexual abuse and non-suicidal self-
injury [11]. Other theoretical models state that PTSD and
comorbid conditions can be accounted for by common under-
lying etiologies or vulnerabilities (see for an overview [12•]).
For example, childhood abuse has been implicated in the de-
velopment of both PTSD and borderline personality disorder
(e.g., [13, 14]) and depression and PTSD have been found to
share an underlying factor of negative affect (see e.g., [15]).
Also, reciprocal models have been proposed, suggesting that
PTSD may influence comorbid conditions and vice versa. For
instance, substance abuse may lead to high-risk behavior,
which can lead to victimization and subsequently PTSD. Con-
versely, PTSDmay lead to higher substance use as a means of
self-medicating (see also [16]). In addition, explanations for
the high comorbidity could be more conceptual and due, for
example, to symptom overlap. This has been argued in the
case of PTSD and comorbid major depression, as the two
disorders share common symptoms such as anhedonia, insom-
nia, and difficulty concentrating (e.g., [17]). Recently, a net-
work model of comorbidity was explicated by Borsboom and
colleagues [18] that proposed that comorbidity arises due to
causal relations between symptoms. The pathways between
these symptoms may be different for each person, which helps
explain the complexity in studying comorbidity, although gen-
eral patterns may arise from the network analyses. For PTSD,
for instance, Frewen and colleagues [19] found evidence for a
perceived causal role of the re-experiencing of traumatic
memories in exacerbating symptoms of depression. The com-
plexity of studying comorbidity in PTSD is further illustrated
by the fact that the number of symptom combinations (PTSD
symptoms in combination with symptoms of comorbidity) as
currently defined by the DSM-5 is over one quintillion [20].
In conclusion, comorbidity between PTSD and other
mental disorders is high, the relationships between PTSD
and other comorbid conditions is complex, and much
more research is needed to unravel possible underlying
mechanisms. Importantly, however, regardless of the spe-
cific theoretical model explaining the relationship between
PTSD and comorbidity, in our view, current models do not
predict that comorbid symptoms will increase as a result
of trauma-focused treatment, as many clinicians may fear.
On the contrary, one of the clinical implications of these
theoretical models about comorbidity is that, when the
PTSD symptoms are successfully treated, comorbid symp-
toms will decrease or, at least, stay stable.
Review Methods
In this article, we will review the secondary outcomes of stud-
ies that target PTSD symptoms using PE. Therefore, we
reviewed the randomized controlled studies (RCTs) that were
included in Powers et al.’s meta-analysis of PE in 2010 [4] as a
starting point and added relevant information from more re-
cent RCTs. We also searched for studies that used data from
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these RCTs about secondary outcome effects. To that end, we
searched in PsychInfo with the following search terms:
“prolonged exposure or prolonged exposure therapy,” “PTSD
or posttraumatic stress disorder,” and “randomized.” The
search was supplemented by consulting experts and reviewing
the references in the studies, and inclusion and exclusion
criteria were evaluated by all authors. Because we were spe-
cifically interested in the secondary effects of PE as a stand-
alone therapy, we excluded studies that used PE in combina-
tion with any medication or placebo [21–23] or integrated or
combined with other psychological treatments [24–27]. As
secondary outcomes, we focus on the most frequent comorbid
conditions (major depression, anxiety disorders, substance use
disorders, personality disorders, and psychotic disorders) and
additional symptomatic features (suicidality, dissociation,
negative cognitions, negative emotions, and problems with
regard to general health and work/social functioning). The
main question was the following one: do comorbid symptoms
and additional symptomatic features decline along with the
PTSD symptoms or at least remain stable as the theoretical
models predict? In Table 1, we present an overview of the
studies.
Major Depressive Disorder
Prevalence Several large epidemiological studies and meta-
analysis consistently show an association between PTSD and
depression. In a large US epidemiological sample, between 48
and 55 % of individuals with PTSD had comorbid major de-
pressive disorder (MDD) [1]. In another large US epidemio-
logical sample, using tetrachoric correlations, PTSD and
MDD were significantly associated with one another (0.50)
[28]. Finally, a large meta-analysis (k=57 studies; N=6670)
showed that 52 % of individuals with current PTSD had co-
morbid MDD (95 % CI 48–56 %) [29]. These studies clearly
indicate that PTSD and depression often occur together.
Theoretical Models/Proposed Mechanisms As mentioned
above, PTSD shares diagnostic symptoms with MDD, includ-
ing anhedonia, difficulty sleeping, irritability, and difficulty
concentrating. Besides shared non-specific symptoms, PTSD
and MDD may also share underlying constructs such as neg-
ative affect, distress, or neuroticism (e.g., [30]). Neuroticism
has a substantial genetic loading and may function as a shared
vulnerability factor across anxiety and depression (e.g., [31]).
Patterns of increased amygdala activation and decreased me-
dial or left dorsolateral prefrontal cortex activation to trauma
or negative stimuli are also consistently found in individuals
with PTSD and depression (e.g., [32, 33]). There may also be
shared genetic, molecular, and neuroanatomical overlap of
regulatory mechanisms across fear extinction and
depression-like behavior [34]. Finally, shared epigenetic
factors may be in play, such that exposure to environmental
stress can produce long-lasting changes in DNA methylation
related to the pathophysiology of both PTSD and depression
(e.g., [35]). These models argue that PTSD and depression
symptoms will likely vary together and that successful treat-
ment may have downstream positive effects on epigenic
expression.
Findings From PE RCTs Of the RCTs for PE, only one [36]
reported rates of pre- and post-treatment diagnosis of MDD.
At pre-treatment, 47.5 % of those in PE met criteria for MDD;
at 9-month follow-up after treatment, 29.5 % of patients in PE
had a MDD diagnosis. Of those participating in long-term
follow-up (mean 6 years later), only 6.9 % of patients in PE
had a MDD diagnosis [37]. Similar, long-term gains were
found for depression severity.
All of the major RCTs for PE report depression severity as
an outcome measure. When waiting list or non-active control
conditions are utilized, PE consistently shows medium to
large effect sizes on depression symptoms, which are main-
tained through follow-up [36, 38–42, 43••, 44, 45, 46••, 47••].
When compared with another trauma-focused treatment, sim-
ilar size pre- to post- and pre- to follow-up gains are consis-
tently reported [40–42, 48–51]. Thus, there is consistent and
strong evidence that PE produces substantial gains in depres-
sion, which are maintained over time.
Secondary data analyses from these RCTs help to further
isolate how the change process for PTSD and depression oc-
curs. Two studies suggest that changes in PTSD symptoms
[52] or related trauma beliefs [53•] drive changes in depres-
sion symptoms in PE, rather than the converse. Thus, in PE,
there is emerging evidence that reduction in PTSD symptoms
promotes reduction in depression symptoms.
Discussion As would be expected given the shared symptoms
and potential etiological factors, PE shows strong and
sustained treatment effects on depression. One of the most
striking findings is the consistency of the effects across stud-
ies. Further, within PE treatment, changes in PTSD symptoms
appear to drive changes in depression, with these findings also
replicated in an open trial [54]. Two caveats should be noted.
First, RCTs are lacking in military trauma samples, though
one large RCT does exist for military sexual assault [45] and
open trials are encouraging and show similar effect sizes (e.g.,
[55, 56]). Second, although the vast majority of the trials allow
for comorbid MDD, they typically require that PTSD be the
primary diagnosis and that the MDD patient does not have
current suicidal intent or plan, though ideation is allowed.
Thus, although the reviewed trials routinely include patients
with depression in the severe clinical range, the current PE
data is limited to patients where trauma exposure and related
PTSD symptomatology are more severe than the depression,
reflecting appropriately focused clinical care.
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Anxiety Disorders
Prevalence Anxiety disorders are among the most com-
mon comorbid diagnoses found in individuals with
PTSD. In epidemiological research, men and women
with PTSD are significantly more likely than those
without PTSD to meet criteria for each of the other
anxiety disorders (men: OR=3.0–5.9, women: OR=
2.4–3.4) and prevalence rates for each anxiety disorder
range from 7.3 to 31.4 % [1]. Comorbidity rates be-
tween PTSD and other anxiety disorders are even higher
in clinical samples. For example, a study of civilian
outpatients found that those with a primary PTSD diag-
nosis met criteria for an average of 1.6 comorbid anxi-
ety disorders, with the highest rates found for general-
ized anxiety disorder (51 %), panic disorder (44 %), and
social phobia (43 %) [57].
Theoretical Models/Proposed Mechanisms PTSD has been
shown to increase the risk of subsequent onset of each of the
anxiety disorders, and this elevated risk disappears upon re-
mission of PTSD [58]. This may be due to common underly-
ing mechanisms (e.g., anxiety sensitivity [59]) and/or symp-
tom overlap (e.g., behavioral avoidance of feared situations is
common in each anxiety disorder).
Findings From PE RCTs Despite the high comorbidity be-
tween PTSD and other anxiety disorders, no studies have
evaluated the impact of PE on specific anxiety disorder diag-
noses or symptoms. However, seven RCTs of PE have includ-
ed a measure of general anxiety as a secondary outcome [39,
40, 42, 44, 45, 50, 60]. All seven studies reported a significant
reduction in general anxiety in PE from pre- to post-treatment,
and gains were maintained after treatment at 3 [42], 6 [44, 45,
60], 12 [40], and 15months [50]. In addition, Power et al. [50]
found rates of clinically significant change in anxiety during
PE ranging from 29 to 33 % for self-reported anxiety to 62–
65 % for interviewer-rated anxiety.
Discussion There is strong evidence indicating that PE
leads to a significant reduction in general anxiety that is
maintained after treatment and no evidence to suggest
that PE worsens general anxiety. Although not evaluat-
ing PE specifically, a systematic review of PTSD treat-
ment studies involving patients with comorbid panic
disorder found that after successful trauma treatment,
the majority of patients (56 %) no longer met panic
disorder criteria [61]. Of note, the opposite has not been
found to be true, namely, successful treatment of panic
disorder among individuals with PTSD does not appear
to lead to changes in PTSD [62]. Future research would
benefit from evaluating the impact of PE on specific
comorbid anxiety disorder diagnoses and symptoms.Ta
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Substance Use Disorders
Prevalence An association between PTSD, increased sub-
stance use, and the development of substance use disorders
has been well-documented in the literature [63, 64]. Epidemi-
ological research indicates that approximately two thirds of
men and womenwith PTSD develop a co-occurring substance
use disorder, most commonly alcohol, sedative, and cannabis
use disorders, either at the same time or subsequent to the
onset of PTSD [1, 65].
Theoretical Models/ProposedMechanisms Research examin-
ing the functional relationship between PTSD and substance
misuse has identified a mediating role of avoidant coping
mechanisms (i.e., use of substances to cope, often referred to
as self-medication) [66–68], and studies examining the tem-
poral relationship between changes in PTSD and substance
use indicate that improvements in PTSD symptom severity
are associated with subsequent improvements in substance
use [69, 70]. One could therefore assume that substance use
outcomes may improve with PE; however, it has only been
very recently that studies have examined this relationship.
Findings From PE RCTs PE was traditionally considered in-
appropriate for use among patients with substance use disor-
ders due to safety concerns [71]. These concerns also led to
the exclusion of patients with substance dependence (and in
some cases abuse) from most trials of PE [8••]. Aside from
assessing substance use for the purposes of exclusion, very
few studies have included measures of patients’ substance
use, and fewer still have reported on them. Of the 13 studies
reviewed by Powers et al. [4], only four report having mea-
sured patients’ substance use [42, 44, 45, 49] at pre-treatment,
and, of those, only one reported on substance use as a second-
ary outcome [45]. Schnurr and colleagues [45] examined
changes in patients’ scores on the Addiction Severity Index
(ASI) in relation to alcohol and other drug use (i.e., heroin,
methadone, other opiates, barbiturates, sedatives, cocaine, am-
phetamines, cannabis, hallucinogens, inhalants) as a second-
ary outcome in their RCT examining the efficacy of PE rela-
tive to present-centered therapy (PCT) among 288 female vet-
erans and active duty personnel. At post-treatment and over
the follow-up period of 6 months, no significant changes in
alcohol or drug use were found for patients who received PE.
Since Powers and colleagues [4] conducted their meta-
analysis, Pacella and colleagues [47••] investigated substance
use outcomes (defined as the cumulative number of days sub-
stances were used in the last month) among 65 patients living
with HIV randomized to receive PE or weekly monitoring.
Eleven substances were assessed including alcohol, marijua-
na, cocaine, ecstasy, amphetamines, GHB, PCP, hallucino-
gens, rohypnol, ketamine, and heroin. Similar to the results
of Schnurr and colleagues [45], no significant increases or
decreases in substance use were found at post-treatment or at
3-month follow-up.
Discussion The small number of studies conducted to date
does not provide sufficient evidence to draw firm conclusions
regarding the impact of PE on substance use outcomes. None-
theless, the evidence thus far suggests that PE does not lead to
an exacerbation of substance use or severity of substance use
disorder. It is recommended that measures of substance use,
including tobacco, be included routinely in future research
studies and in clinical practice. These assessments should be
undertaken pre-, post-, and during treatment to allow for a
thorough examination of the relationship between changes in
PTSD symptoms and substance use.
Personality Disorders
Prevalence A meta-analysis of 125 studies of clinical and
non-clinical samples found that 35 % of adults with PTSD
also had at least one personality disorder, with the most com-
mon being paranoid (26 %), avoidant (23 %), and borderline
(22 %) [72]. Among clinical samples of PTSD patients with
various trauma types, the rate of co-occurring personality dis-
order is even higher (e.g., 39–79 %; [73–75]).
Theoretical Model Several theories have been proposed to
account for the high comorbidity between PTSD and person-
ality disorders. Childhood abuse and adversity have been im-
plicated in the development of both PTSD and personality
disorders (e.g., [13, 76, 77]). In addition, PTSD may maintain
or exacerbate problems associated with personality disorders.
For example, PTSD has been found to increase core features
of borderline personality disorder such as emotion dysregula-
tion and recurrent suicidal and self-injurious behavior (e.g.,
[25]). Finally, the high comorbidity may be at least partially
explained by symptom overlap between PTSD and some per-
sonality disorders, such as affective reactivity in borderline
personality disorder and detachment from others in paranoid
personality disorder. These models suggest that improvements
in PTSD would likely lead to improvements in personality
disorders that either developed in response to traumatic events
or are being exacerbated by PTSD and associated problems.
Findings From PE RCTs None of the RCTs of PE in this
review excluded individuals on the basis of a personality dis-
order diagnosis. However, individuals with a primary diagno-
sis of a personality disorder would have been excluded from
most studies. Although several studies have evaluated the im-
pact of personality disorders on PTSD and related symptoms
after PE [75, 78, 79], to date, no studies have yet evaluated the
impact of PE on personality disorder symptoms.
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Discussion Given the high prevalence of personality disor-
ders among individuals with PTSD, the ability of PE to reduce
co-occurring personality disorder symptoms is an important
question to examine in future research.
Psychosis
Prevalence The rate of PTSD in patients with a psychotic
disorder is estimated to be 12.4 % (95 % CI 4.0–20.8 %;
[80]). Despite this relatively high rate of comorbidity, in clin-
ical practice, PTSD is largely underdiagnosed in this popula-
tion. Conversely, psychotic symptoms occur frequently in
PTSD patients (15–64 %; see for a review [81]), although
others find lower rates (17 %) when other comorbid condi-
tions are controlled [82].
Theoretical Models/Proposed Mechanisms There is, howev-
er, much attention in regard to the relationship among trauma,
PTSD, and psychosis [83–86]. Many studies found evidence
for the causal relationship between childhood trauma and the
development of psychosis [87]. Further, in many models, it is
stressed that symptoms of PTSD and psychosis negatively
interact with each other [10, 84], that they share some symp-
toms (such as intrusions and paranoia), and that they share
developmental and maintenance processes (e.g., a self-
blaming attributional style and avoidance behavior) [84].
Based on these models, it can be understood that when PTSD
symptoms decrease during treatment, the psychotic symptoms
may decrease along with them.
Findings From PE RCTs Despite these strong relationships
between PTSD and psychosis, little is known about the effects
of trauma-focused treatment such as PE in this patient popu-
lation. Most clinicians fear that this patient population may be
too vulnerable to tolerate trauma-focused treatments [6], and
psychosis (especially not medically stabilized and current psy-
chosis) is a frequently used exclusion criterion in PTSD treat-
ment trials [88]. Accordingly, in most studies of Powers’
meta-analysis [4], patients with a current and/or past psychosis
were excluded; consequently, these studies do not provide
information about changes in psychotic symptoms during PE.
More recently, several studies have been conducted that in-
clude patients with psychotic disorders, including current psy-
chotic disorders and schizophrenia. In a multiple baseline ran-
domized controlled design, de Bont and colleagues [89••]
found evidence for the feasibility, effectiveness, and safety
of trauma-focussed treatments, including PE, in either past
or present psychotic patients (N=10), with comparable effect
sizes as in PTSD populations without psychosis. In addition,
no treatment-related increases were found in hallucinations or
delusions during or after PE. In addition, psychosis-prone
thinking significantly declined during treatment. In a large
multi-site RCT with PTSD patients with past or present psy-
chotic disorder (the majority of patients had schizophrenia or
schizoaffective disorder; N=155 [90••]), PE was found to be
feasible, safe, and effective, with large effect sizes that are
comparable to studies including PTSD patients without psy-
chosis. Compared with waiting list, no more severe adverse
events (including psychiatric hospital admissions and suicide
attempts) occurred during PE.
Discussion In conclusion, though many more studies are nec-
essary, the available research indicates that some psychotic
symptoms (especially psychosis-prone thinking) decline
along with PTSD symptoms after PE. The changes in
psychosis-related thinking may be related to changes in
trauma-related cognitions, such as beliefs about safety and
trust, as these cognitions have a substantial overlap with de-
lusional and paranoid thinking. No changes were found for
other psychotic symptoms (e.g., hallucinations). Notably, no
increases in psychotic symptoms were found during PE as
many clinicians fear.
Suicidality
Prevalence Individuals with PTSD are at heightened risk of
suicidal ideation and behavior. A recent meta-analysis found a
large overall effect size (g=0.78) for the association between
PTSD and suicidality, and this link was significant for both
suicidal ideation and suicide attempts, across different trauma
samples (e.g., combat veterans, physical/sexual abuse, natural
disasters) and in clinical and non-clinical samples [91].
Theoretical Models/Proposed Mechanisms Several theoreti-
cal models have been proposed to explain the relationship
between PTSD and suicidality. Some models suggest that cer-
tain PTSD symptoms directly increase suicide risk; for exam-
ple, more severe re-experiencing and numbing symptoms, in-
cluding physiological reactivity to trauma cues, inability to
recall parts of the trauma, and a sense of a foreshortened future
are directly associated with suicide attempts [92]. Other
models highlight the role of various cognitive-affective pro-
cesses as direct or indirect mediators between PTSD and
suicidality, including perceptions of defeat and entrapment
(e.g., [93]), negative self-appraisals (e.g., [94]), hopelessness
(e.g., [91]), and guilt and shame (e.g., [95]). In addition, some
models propose that the link between PTSD and suicidal be-
havior is partially explained and/or compounded by other co-
morbid problems such as functional impairment [96], depres-
sion [97], sleep disturbance [98], and alcohol dependence
[99]. Taken together, these models suggest that treating PTSD
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is likely to reduce suicidality directly by reducing PTSD
symptoms and indirectly by reducing established cognitive
and affective mediators as well as other compounding
problems.
Findings From PE RCTs Despite the high rate of suicidality
among individuals with PTSD, suicide-related outcomes are
rarely reported in PTSD treatment research, including studies
of PE. This is likely due to the fact that acutely suicidal pa-
tients are typically excluded from these studies [88]. The ex-
clusion of acutely suicidal patients is due to concerns that
trauma-focused treatment may exacerbate suicidality (e.g.,
[6]). As with other PTSD treatments, PE excludes individuals
with a recent history of suicidal or severe self-injurious behav-
ior (typically the last 3 months) and/or individuals believed to
be at imminent risk of suicide such as those with suicidal
intent and/or a plan [100]. Although patients with non-acute
suicidal ideation are generally included in PE treatment stud-
ies, only one study has evaluated the impact of PE on suicidal
ideation [101]. This study used secondary data from the RCT
[36] of female rape survivors with chronic PTSD in which
participants were excluded if they reported suicidal intent or
current parasuicidal behavior. In this study, the proportion of
PE patients endorsing any suicidal ideation on a single-item
measure decreased significantly during treatment (from ap-
proximately 24 to 10 %) with further slight decreases found
across up to 10 years of follow-up [101]. However, changes in
PTSD did not predict reductions in suicidal ideation in PE
after controlling for the effects of major depression and hope-
lessness. Thus, the mechanisms underlying the reduction of
suicidal ideation in PE were not clear.
In addition, one study evaluated the rate of suicidal behav-
ior and non-suicidal self-injury during PE among five patients
with comorbid PTSD and psychotic disorders [89••]. This
study excluded patients with acute suicidality but included
those with non-acute suicidal ideation. Suicidal and non-
suicidal self-injury were measured at every treatment session,
and no instances of either behavior were reported during PE,
indicating that suicidality does not increase during PE. In a
large randomized controlled trial of 155 patients with comor-
bid PTSD and psychotic disorders [90••], patients with higher
levels of suicidality were included. In PE, at baseline, 62.3 %
had a history of attempting suicide and 50.9 % had current
medium or high levels of suicide risk. Suicidality was checked
every session, and in comparison with the other treatments
(active treatment and waiting list), no more adverse events
involving suicidality occurred during PE.
Discussion There is no evidence that PE exacerbates
suicidality, and there are no reports of completed suicides in
any PE study. However, there is currently insufficient research
to draw firm conclusions about the impact of PE on suicide-
related outcomes. Although the available research does not
support common clinician concerns that PE may exacerbate
suicidality, it is also limited by its exclusion of individuals
with acute suicidality and its reliance on relatively low-risk
samples with low base rates of suicidality. Future research
would benefit from the inclusion of standardized measures
of suicidality both during and after PE. In addition, studies
are needed to evaluate whether these effects generalize to
higher risk populations, such as those with a recent history
of suicidal behavior and/or current suicidal intent or plans,
or whether treatments that include a stabilization phase prior
to trauma processing may be necessary for higher risk patients
(e.g., [102]).
Dissociation
Prevalence Many PTSD patients have at least some symp-
toms of dissociation. Some dissociative symptoms, such as
flashbacks, numbing, and psychogenic amnesia, are included
in the PTSD DSM-5 diagnostic criteria and are, as such, con-
sidered part of the diagnosis of PTSD. Other dissociative
symptoms, such as derealization, depersonalization, and cur-
rent reduction in awareness are usually established apart from
the PTSD diagnosis. For patients scoring high on these symp-
toms, the DSM-5 [103] has a “dissociative subtype” specifier.
In a veteran sample, 12 % of the PTSD patients showed ele-
vated symptoms of derealization and depersonalization [104].
Other studies showed that 15 % (men, Vietnam veterans) to
30 % (women, veterans with high rates of sexual abuse) [105]
of PTSD patients were classified into the dissociative subtype.
In civilian samples, a 15–25% rate of this dissociative subtype
was found [106, 107]. In sum, about 12–30 % of the PTSD
patients show elevated dissociative symptoms. However, it
should be noted that other studies did not find dissociation
to be a taxon in PTSD but instead situated on a dimensional
scale within PTSD [108, 109], suggesting that as PTSD symp-
toms increase, so do dissociative symptoms and vice versa.
Theoretical Models/Proposed Mechanisms Many clinicians
(51 %) assume that any form of dissociation is a contraindi-
cation for exposure therapy [6]. Theoretically, it is assumed
that severe dissociation may hinder fear activation and thereby
emotional processing, which is a crucial element underlying
the working mechanism of PE [110]. In line with this view
(see for an overview [111]), dissociation is regarded as a cop-
ing strategy to deal with the extreme arousal elicited by
recalling of trauma-related memories during exposure. This
coping strategy is referred to as “emotional overmodulation”
which leads to hyperinhibition of the amygdala activity, with
fear inhibition as a result. Therefore, it is assumed that the
emotional arousal that is evoked by PEmay lead to an increase
in dissociation in order to cope with the high fear levels.
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However, one could also reason that when PTSD symptoms
decline during treatment, this dissociative coping strategy is
less needed, and as a result, dissociative symptoms will also
decrease.
Findings FromPERCTs In three of the studies included in the
meta-analysis of Powers, dissociation was measured as a sec-
ondary outcome measure. In a sample of childhood sexual
abuse victims, after exposure therapy, self-reported symptoms
of dissociation (Dissociative Experiences Scale [DES] [112,
113]) decreased, though this decline was not significant [60].
In rape victims, self-reported symptoms of dissociation (DES)
decreased significantly after PE [44]. In victims of mixed
trauma, symptoms of numbing (assessed via the Clinician-
Administered PTSD Scale [CAPS] numbing subscale) signif-
icantly declined after PE [51]. At post-treatment, 47 % of the
patients that received PE showed clinically significant reduc-
tions in numbing; at 3 months follow-up, this was 53 %. In
addition, clinician-rated dissociative symptoms, as measured
with three additional items of the CAPS, significantly de-
clined after PE.
Discussion Although dissociative symptoms are thus far not
systematically evaluated after PE, the studies that did include
dissociation showed that dissociative symptoms, both self-
reported and clinician-rated, significantly decline after PE. It
is, however, not known if these decreases in dissociative
symptoms also hold for PTSD patients with severe dissocia-
tive symptoms, for instance patients that fulfill diagnostic
criteria of the PTSD dissociative subtype. In light of the newly
introduced diagnostic dissociative subtype of PTSD, it is
strongly recommended that future studies include secondary
measures (both self-report and clinician-rated) of derealization
and depersonalization. Further, dissociation is thus far only
operationalized in terms of detachment symptoms, while dis-
sociation is a broader concept (see [114]). Therefore, it is
recommended that also somatoform dissociation and symp-
toms of compartmentalization, such as conversion disorder
symptoms or symptoms of tonic immobility, are included.
Negative Cognitions and Emotions
Prevalence Negative cognitions about oneself (e.g., I am in-
competent), the world (e.g., No one can be trusted), and self-
blame (e.g., I should have been able to stop it), as well as
negative emotions such as shame, guilt, and anger, are com-
monly associated with PTSD, though not every individual
with PTSD reports these at extreme or dysfunctional levels.
In a recent US national epidemiological study, of those with
probable PTSD, 35 % reported negative beliefs, 34 % guilt or
shame, and 30 % anger or aggression symptoms in the past
month [115]. These numbers are in contrast with other PTSD
symptoms which occur at higher levels among those with
probable PTSD, such as re-experiencing (52 %) and avoid-
ance of trauma-related thoughts (53 %; [115]). This is consis-
tent with these secondary symptoms being much more related
to idiosyncratic trauma characteristics (e.g., I did not stop my
sister from also being abused) or pre-existing individual dif-
ferences (e.g., I always had a temper).
Proposed Working Mechanism Although it may not be intui-
tive to some that an exposure-based treatment such as PE
would target these secondary symptoms, particularly without
elements such as cognitive restructuring or anger manage-
ment, current theories argue against this. Emotional process-
ing theory emphasizes the role of providing corrective infor-
mation and altering cognitive meaning elements of the fear
schema as critical for recovery; in contrast, anger is viewed
as a form of avoidance that impedes accessing the fear schema
and recovery [5]. Other theorists also highlight the role of new
inhibitory learning (e.g., [116]), cognitive shifts during expo-
sure (e.g., [117]), and changes in negative appraisals [118]
underlying recovery.
Recently, Litz and colleagues [119] put forth the construct
of moral injury, arguing that particularly with combat trauma,
individuals may act in ways that contradict deeply held moral
beliefs or experience conflict about the unethical behaviors of
others. They suggest interventions such as PE may not be
sufficient to address these issues. Others have argued that PE
is able to flexibly address guilt, shame, and anger related to
moral injury (e.g., [120]). Accordingly, although some theo-
rists have raised concerns, main theoretical models predict that
these secondary symptoms will reduce as PTSD symptoms
reduce or may even underlie reductions in PTSD symptoms.
Results From PE RCTs Secondary data analyses, reporting
psychometrically validated measures of these constructs in
the large randomized trials, show small to large decreases
and sustained improvement in negative cognitions [39, 42,
47••, 60, 90••, 121], trauma-related guilt [36, 122], and anger
[122, 123]. One study [60] failed to find changes in hostility
and anger, though in this study improvement in other domains
including PTSD was also limited arguing against this finding
being specific in regard to anger. Single-item measures of
trauma-related guilt and anger also show moderate to large
pre- to post-treatment and pre- to follow-up effects for PE
[49, 51]. Though some have raised concerns that initial anger
may impede PTSD symptom reduction, increase PE dropout,
or worsen these symptoms, this has not been consistently seen
[122, 123]. Variability in the expression of these associated
features may help explain the range of observed effects; that
is, an individual with little or no initial anger, guilt, or distorted
cognitions has no statistical room for improvement. Indeed,
effect sizes actually tend to increase (e.g., [123]) or stay the
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same [122] when individuals with more extreme initial scores
are examined.
Discussion Taken together, these studies argue that PE re-
duces negative cognitions and emotions without explicit cog-
nitive restructuring procedures. Across studies, particularly
for those with more severe negative beliefs, guilt or shame,
and anger, PE reduces these secondary symptoms. In particu-
lar, for guilt, shame, and anger, the routine use of psychomet-
rically validated measures is needed to further strengthen these
conclusions. Changes in cognitions are related to changes in
PTSD severity [121] or may even drive these changes [53•].
Interestingly, the explicit addition of cognitive restructuring
does not appear to augment cognitive changes [121] and
may even impair changes for those with extreme negative
cognitions [124]. Additional research with larger samples
and subsamples of males and veterans is needed.
General Health and Work/Social Functioning
Prevalence PTSD is related to both general health problems
and lower social functioning. In a meta-analysis, Pacella and
colleagues [47••] found elevated rates of general physical
health problems and general medical conditions in persons
with PTSD. In addition, specific medical conditions were
found to be related to PTSD, such as cardiovascular symp-
toms, gastrointestinal symptoms, and pain.
Social functioning is generally low among PTSD patients;
for instance, 70 % of PTSD veterans and their partners report-
ed clinically significant levels of relational distress [125].
Work and school functioning is also lowered and social con-
tacts are limited. In line, in a sample of primary care anxiety
patients, of all anxiety disorders, PTSD was most consistently
related to lower levels of functioning, including general health
and social functioning [126].
Rationale/Proposed Working Mechanism Several studies
showed that PTSD symptoms mediated the relationship be-
tween traumatic experiences and general health problems (see
for a review [127]). Several studies have shown that PTSD-
related biological markers such as abnormal electrocardio-
graph (ECG) results, high white blood cell counts, and T cell
counts [128] can explain high rates of cardiovascular and
auto-immune diseases among PTSD patients.
In a meta-analysis [129], lack of social support was
strongly related to the development of PTSD, indicating that
good social functioning contacts may be a buffer against post-
traumatic stress. Conversely, however, specific PTSD symp-
toms, such as numbing, lack of interest, and cognitive distor-
tions about safety and trust, may cause problems in social
functioning. Accordingly, in a large sample (N=2249), it
was indeed found that PTSD predicted lack of social support
[130].
Because general health problems and lower social func-
tioning after trauma have been shown to be moderated by
PTSD symptoms, it is expected that general health and social
functioning will increase in line with a decrease in PTSD
symptoms.
Results From PE RCTs In most studies that included health
as an outcome measure, general (physical) health problems
were found to be significantly improved after PE [38, 131,
132], as was sleep quality [131, 133]. Also, in a more
recent RCT in a medical sample (HIV patients), evidence
was found for improvements of physical health and in-
creased short-term adherence to medical medication after
PE [47••]. What is more, in the Rauch et al. study [47••],
evidence was found that changes in PTSD symptoms (and
not in depressive symptoms) contributed to the change in
physical health. For patients with PTSD due to a cardio-
vascular event, it was shown that there were no significant
relevant increases in vital signs during or after PE, includ-
ing blood pressure, arterial pressure, and pulse [46••]. Al-
so, no adverse events, such as death or recurrent myocar-
dial infarctions, happened.
In most studies, work and social functioning were included
as secondary outcome measures. In all studies that measured
work and social functioning, significant increases were found
in work functioning [38, 41, 49] and quality of life [45, 60]
after PE. Also, social adjustment and functioning [40, 41,
43••, 49, 50] increased after PE. In addition, quality of life
was significantly improved after PE [45, 60].
Discussion In line with the hypotheses, based on the idea
that PTSD symptoms moderate the relationship between
trauma and general functioning, the findings were very
consistent in that both general health and social functioning
improved along with the PTSD symptoms after PE. This is
highly important information in light of cost-effectiveness
issues, given the fact that PTSD patients have high medical
care consumption and low social and work functioning. In
terms of physical vital signs, PE proved to be not danger-
ous, not even in a vulnerable patient group with cardiovas-
cular problems. That finding suggests that PE can be safely
provided for medical populations also.
In only a few studies, general health was included as a
secondary measure. Given the high medical consumption of
PTSD patients, however, and especially for cost-effectiveness
purposes, it may be recommended to include this measure in
future studies. The same goes for social functioning and work
functioning. Additionally, given that social support is an im-
portant predictor of PTSD symptoms, changes in social sup-
port, as a specific element of social functioning, may be
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crucial to include as a secondary measure, for instance to
predict relapse in PTSD symptoms.
Conclusions
In this review, we presented an overview of results regarding
secondary outcomes of PE, including several comorbid con-
ditions and additional symptomatic features. For some areas
of comorbidity, there is strong evidence that PE leads to im-
provements in these secondary outcomes: depression, general
anxiety, trauma-related cognitions, and overall functioning.
For other comorbid symptoms, however, relatively little sys-
tematic research has been done, not all relevant comorbid
conditions were included, and secondary outcome measures
varied highly across the studies, thereby limiting the ability to
draw firm conclusions. That being said, based on the available
data, a very consistent picture emerged from all studies and
across all secondary outcomes. Consistent with our hypothe-
sis, results consistently showed that comorbid conditions and
additional symptomatic features decreased along with the
PTSD symptoms (depression, general anxiety, problems in
social and work functioning, dissociation, physical health
problems, trauma-related negative cognitions and emotions)
or at least did not increase during PE (substance abuse, delu-
sions, hallucinations, suicidality). None of the studies found
an increase for any of the comorbid conditions under study.
These findings are in line with several theoretical models
about PTSD and comorbidity, as outlined in the “Introduc-
tion” section. In these models, PTSD symptoms are usually
regarded as moderators and/or mediators of the relationship
between trauma and comorbid conditions, suggesting that
when PTSD symptoms decrease, the associated comorbid
conditions are likely to also decrease. Of note, however, few
studies have evaluated whether changes in PTSD are directly
or indirectly associated with improvements in secondary out-
comes. For example, PE has been shown to significantly re-
duce depression in all studies, and it is possible that changes in
some comorbid conditions (e.g., suicidality, social function-
ing) after PE may be specifically attributed to a decline in
depression instead of or in addition to a decline in PTSD
symptoms. This may be an indirect process when, for exam-
ple, PTSD symptoms change first and lead to subsequent
changes in depression [52]. Alternatively, reductions in PTSD
symptoms, but not depression, may be directly associatedwith
improvements in other areas; for example, changes in physical
health after PE are more related to changes in PTSD symp-
toms than to changes in depression [134]. In future studies, to
shed more light on the underlying mechanisms, it is recom-
mended that direct and indirect pathways between changes in
PTSD and secondary outcomes are evaluated.
Some comorbid conditions and associated symptoms were
more likely to change as a result of a decrease of PTSD
symptoms than others. Depression and general anxiety, for
instance, were consistently found to decrease along with the
PTSD symptoms, while other conditions, such as substance
abuse and hallucinations, tended to remain stable. This may be
due to the fact that some disorders (e.g., major depression and
PTSD) share more symptomatology and underlying etiology
than others (e.g., psychotic disorders and PTSD). Also, co-
morbid disorders may improve in some patients, and not in
others, due to different pathways for the comorbidity (e.g.,
[18]). For example, a patient could first have an onset of psy-
chosis and then be exposed to trauma and develop PTSD. Or a
patient could have experienced childhood sexual assault, de-
veloped PTSD, and then, when he or she reached a high-risk
age, developed psychosis. This differential relatedness of co-
morbid conditions with PTSD symptoms may lead to differ-
ences in changes of comorbid symptoms a result of PTSD
treatment. Therefore, it is recommended that future studies
explicitly attempt to assess the interrelatedness, including
timing of onset, between the comorbid conditions and PTSD.
These findings have several implications. From a clinical
point of view, these studies consistently show that fears of
long-term exacerbation of comorbid conditions or deteriora-
tion of functioning as a result of PE are not valid reasons for
excluding many PTSD patients from an effective trauma-
focused treatment. It was not our goal in this article to evaluate
the efficacy of PE with regard to decreases in comorbid symp-
toms in comparison to other trauma-focused treatments, such
as cognitive therapy or eye movement desensitization and
reprocessing (EMDR). Based on the theoretical models,
changes in comorbid symptoms are not expected to relate
exclusively to PE but may generalize to other effective
trauma-focused treatments as well. Note, however, that for
other trauma-focused treatments, different pathways to chang-
es in comorbid conditions may appear. For PE, the conclusion
that comorbid symptoms do not increase by the end of treat-
ment is especially of importance given that some clinicians are
usually more hesitant to use PE in patients with comorbid
conditions than other trauma-focused treatments like EMDR
[7].
We deliberately chose to include only studies in our review
in which PE was used as a stand-alone therapy and excluded
studies that used additional treatment elements such as emo-
tion regulation skills, cognitive therapy, pharmacological
agents, and studies that used integrated treatment approaches
in which both PTSD and the comorbid symptoms are targeted
at the same time. Therefore, wewere able to review changes in
comorbid conditions after PE without the comorbid condi-
tions being explicitly targeted. Our findings that many comor-
bid conditions significantly improve after PE, perhaps as a
result of improvement in PTSD symptoms, call into question
the need to add interventions aimed to change comorbid con-
ditions to PE. Instead, it may be a better approach to evaluate
the remaining comorbid symptoms and associated features
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after PE and, if needed, provide targeted interventions to
achieve full remission for these symptoms.
These findings also question the necessity of phase-
oriented treatment approaches in cases of PTSD and comorbid
conditions (see [24]). In these treatments, the first phase is
usually directly aimed at coping skills to deal with or decrease
comorbid conditions, such as emotion regulation problems
(including dissociation) and poor interpersonal skills. In the
second phase, PTSD symptoms are directly targeted via
trauma-focused treatments such as PE. The rationale for a
phase-oriented treatment approach is that these comorbid
symptoms, when left untreated, will interfere with trauma-
focused treatment, or will increase when the trauma is directly
processed, and must therefore be addressed before trauma
processing. In an RCT, a phase-oriented approach such as
STAIR-PE was found to be more effective than support plus
PE [24], but studies that directly compare a phase-oriented
approach and PE without any pre-phase are still lacking. In
our review, however, we found no evidence for this phase-
oriented view. Instead, we found that when PTSD symptoms
were directly targeted without a preparatory treatment phase,
comorbid symptoms decreased along with the PTSD symp-
toms or at least remained stable. Moreover, a recent study
found evidence for improvements in emotion regulation after
PE as a stand-alone therapy [135•].
Our findings are consistent with theoretical models propos-
ing that several comorbid conditions may derive directly or
indirectly from the PTSD symptoms [10, 18]. Therefore, di-
rectly targeting the PTSD symptoms with a trauma-focused
treatment such as PE would be a logical first step in treatment.
In contrast, adjunctive treatments targeted at specific second-
ary conditions are typically longer and may unnecessarily
postpone decreases in PTSD symptoms and related comorbid-
ity or even increase the risk of dropout before the patient
arrives at the trauma-focused treatment phase. For comorbid
conditions that do not seem to change during PE, such as
substance abuse, integrated treatments in which the PTSD
symptoms and the comorbidity are targeted at the same time
are recommended (see [26]). In addition, for comorbid condi-
tions such as acute suicidality for which PE has not yet been
evaluated as a stand-alone treatment, it is recommended to use
an integrated treatment that focuses on stabilizing suicidality
prior to starting trauma-focused treatment and continues to
monitor and target suicidality as needed during PE (e.g.,
[102]). Future research should be aimed at directly comparing
phase-oriented treatments to PE-alone or integrated treat-
ments. Also, a reverse phase-oriented treatment may be con-
sidered in which PTSD symptoms are targeted in the first
phase and remaining comorbid symptoms are addressed in
the second phase.
From a cost-effectiveness point of view, the finding that
both PTSD and secondary outcomes tend to systematically
decrease may mean that those patients need less care
following their PE treatment. This was nicely illustrated by a
study of Tuerk et al. [136] that measured the mental health
service use of veterans with PTSD in the year before and the
year after PE. They found that for patients who completed PE,
the use of health services decreased significantly. Le and col-
leagues [137] also reported the cost-effectiveness of PE in the
year following treatment, accounting for the cost of usage of
both mental health and broader health services.
One limitation of our review is that the outcome measures
were evaluated at the end of treatment, and clinicians may
worry about exacerbations of PTSD symptoms and related
comorbidity during treatment, especially in the weeks after
the initiation of imaginal exposure. Indeed, there are indica-
tions that the process of PTSD symptom reduction during PE
is quadratic, as symptoms, such as re-experiencing symptoms,
may worsen in the first weeks of treatment before they get
better [138]. As a result, because PTSD symptoms may be
functionally related to some comorbid conditions, the comor-
bid symptoms may also temporarily increase after initiation of
imaginal exposure. Foa and colleagues [139] specifically stud-
ied these patterns of exacerbation of symptoms during PE and
found that only a minority of patients showed exacerbations of
PTSD symptoms (15.4 %) or comorbid symptoms (general
anxiety 28.2 %; depression 12.8 %) after the first imaginal
exposure session. Importantly, however, these exacerbations
were temporary and unrelated to treatment outcome and drop-
out. This means that when a clinician is faced with increases in
symptoms (either PTSD or comorbid symptoms) after initia-
tion of imaginal exposure, it can be expected that if PE is
continued, the symptoms will eventually decrease significant-
ly and the patient will profit as much from the treatment as
patients without initial exacerbations. This is further reified by
a recent large study (N=361) of pooled data across RCTs
[140] showing that, at post-treatment, reliable worsening of
PTSD symptoms after PE was non-existent and reliable wors-
ening of depression was low (1.5%), with no differences from
other trauma-focused treatments (CPT, EMDR).
Another limitation is that comorbidity measures that were
included in the studies were usually measured with self-
reported severity or frequency of symptoms. Therefore, its clin-
ical value may be limited because, despite a statistical decrease
in symptoms, it remains unknown if patients still fulfill diag-
nostic criteria for the specific comorbid disorder and/or whether
this decrease is clinically significant. It is therefore recommend-
ed that future studies evaluate both the clinical and statistical
significance of reductions in comorbid conditions.
For some comorbid conditions, such as personality disor-
ders, secondary outcome measures were lacking in the litera-
ture. Some of this may be an inherent assumption (which may
not be accurate) that personality traits or disorders are fixed
and stable and would be unlikely to change with any form of
treatment. This lack of measurement was also the case for
some comorbid conditions that may be of importance,
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especially for some specific patient populations. For instance,
for studies addressing treatment outcomes in patients with
“complex” PTSD, it may be of importance to include mea-
sures about emotion regulation, self-esteem, and interpersonal
relationships, given their interrelationship with PTSD. Con-
sistent with our findings, a recent study indicated that prob-
lems with emotion regulation also diminished after PE [135•]
in patients with a history of childhood abuse, without any
emotion regulation skill training.
In conclusion, the impact of trauma-focused treatments
such as PE on comorbid conditions is highly clinically rele-
vant given that a vast majority of PTSD patients present with
comorbid problems. Although systematic research is not
available for all comorbid disorders, in the available studies,
a very consistent pattern was found, namely, comorbid disor-
ders and related symptoms tend to decline along with PTSD
symptoms or at least did not increase as a result of PE. This is
consistent with theoretical models emphasizing the moderat-
ing and mediating role of PTSD symptoms between trauma
and psychopathology [10, 18]. Clinically, a fear of exacerba-
tion of comorbid symptoms as a result of PE—given the pop-
ulations that have currently been studied—seems to not be a
valid reason for exclusion of patients from PE.
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